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ABSTRACT
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a mental
health disorder characterized by functional impairment due to symptoms of
inattention, impulsivity, and hyperactivity. Psychostimulant medications
effectively reduce these symptoms, however there is little evidence regarding
the factors associated with use of different types of stimulant medications.
Objective: To investigate factors associated with sustained release (SR)
versus immediate release (IR) stimulant prescription for pediatric ADHD.
Methodology: A cross-sectional observational study was conducted using the
2012 National Ambulatory Medical Care Survey (NAMCS), a nationally
representative sample of physician office visits. Independent predictors of SR
stimulant medication prescription, as compared to IR stimulant prescription,
were identified from logistic regression models.
Results: Our data set contained visits representative of 105,548,504 visits with
an associated age of 4-17 years old (11.39% of all visits). Of these pediatric
visits, there were 7,088,227 visits (7.56%) with an ADHD diagnosis code (ICD9: 314.00, 314.01). The majority of pediatric ADHD visits were male
(n=5,155,695, 72.74%). The most frequent age groups were 7 to 11 years
(n=3,374,121, 47.60%) and 12-17 years (n=46,097, 42.97%), while the 4-6
year age group was less frequent (n=668,010, 9.42%). The most frequent race
was White (n=4,771,295, 67.31%), while less frequent were Black race
(n=1,229,675, 17.35%) and Hispanic race (n=956,710, 13.50%). The most

frequent office region was the South (n=3,221,211, 45.44%). The most
frequent pay types were private insurance (n=3,427,928, 48.36%) and
Medicaid (n=2,473,735, 34.90%).
After applying our study inclusion criteria, there were 4,617,709
pediatric visits with IR or SR prescriptions. Of this visit sample, 3,431,741 had
sustained release (74.35%) and 1,185,968 visits had immediate release
stimulant prescriptions (25.68%). There were 1,969,116 visits with a
combination of SR/IR (42.64%), which we included as SR in our modeling.
Our logistic modeling approach identified a number of non-significant
sociodemographic predictors of SR prescription, relative to IR prescription.
Compared with the 7-11 year old age group, the 12-17 year old group was
70% more likely to have a SR vs IR prescription (OR=1.695), while the 4-6
year old group was roughly 70% less likely to have SR than IR (OR=0.359).
Relative to those with white race/ethnicity, those of black race (OR=2.183),
Hispanic race (OR=2.223), and "Other" race (OR=2.717) had a non-significant
but doubled likelihood of receiving an SR vs IR only prescription. Our logistic
approach did not find evidence that sex or ADHD subtype were significant
predictors of SR vs IR stimulant prescription. Overall, this modeling approach
did not identify any significant sociodemographic predictors of SR vs IR only
use

Conclusions: In our nationally representative sample of pediatric ADHD office
visits, visits of adolescent age or those with comorbid anxiety disorder had a
higher likelihood of a SR stimulant drug mention than an IR mention. In
contrast, visits with a diagnosis of autism and those in the Western region
were less likely to have SR relative to an IR stimulant prescription. We did not
find evidence to support disparities in SR versus IR stimulant prescriptions in
visits of Black, Hispanic, or female children. These findings documented
similarities and differences in ADHD medication prescription across
sociodemographic groups that may be helpful for identifying office visits with a
predisposition towards SR or IR stimulant prescription and to further
understand the choice of ADHD drug for childhood ADHD.
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CHAPTER 1

Background
Attention deficit hyperactivity disorder (ADHD) is defined by persistent
and developmentally inappropriate problems with attention, impulsivity, and
hyperactivity that cause functional life impairments.1,2 Children with ADHD
suffer functional impairments because of symptoms such as forgetfulness,
distractibility, excessive fidgeting, and disorganization.3 Numerous studies
have demonstrated ADHD is effectively and safely treated by a variety of
medications including stimulants like methylphenidate and amphetamine salts,
or the non-stimulant atomoxetine.4-6
There is a national childhood ADHD prevalence of roughly 10%, which
represents over five million children.3,7,8 There is an estimated cost burden of
ADHD between $36 and $52 billion dollars in 2005, due to a loss of
productivity in those with ADHD.9-14 The societal cost burden includes a loss in
the productivity of students and workers, totaling an estimated $3.7 in adult
work costs, and increased healthcare costs due to mental health
comorbidities, unintended injuries, and utilization of behavioral therapy.11,12,1517

Further, relative to their non-ADHD classmates, the five million US children

with ADHD are less likely to succeed in academics13,14 and more likely to
struggle to maintain healthy friendships and familial relationships.9,10 For
instance, children with ADHD report almost 3 times as many peer problems as
those without ADHD (21.1% vs 7.3%) and are almost 10 times as likely to
1

have difficulties with friendships (20.6% vs 2.0%).12 Because these chronic
impairments can lead to consequences like poor grades, low self-esteem, and
hampered social lives, it is understandable that those with ADHD are more
likely to develop comorbidities like depression18,19, anxiety20, and
obesity.11,21,22
In 2011, the American Academy of Pediatrics (AAP) published
guidelines concerning the evaluation, diagnosis, and treatment of pediatric
ADHD.23 This document highlights the strength of evidence for diagnosis of
ADHD via the diagnostic criteria in the Diagnostic and Statistical Manual of
Mental Disorders Version V (DSM-V), the importance of evaluation of common
comorbidities like anxiety and depression, and acquiring symptom information
from different perspectives including parents, teachers, and other clinicians.
Concerning the 4-5 year age group, the AAP suggests that behavioral therapy
should be first and psychostimulant treatment methylphenidate second,
though some research supports the effectiveness of medication alone.4,10,14
These guidelines also suggest that children 6 years or older may have ADHD
medications alone, therapy alone, or a combination of both.
Regarding medication options, there is a plethora of evidence
demonstrating the effectiveness of stimulants for the treatment of ADHD.
Since the 1937 study of Charles Bradley, stimulants have been proven to be
effective for the reduction of hyperactivity, impulsiveness, and short attention
span24. In his original Bradley's study of stimulants for the treatment of severe
headaches from pneumoencephalograms, Bradley observed a striking
2

improvement in the behavior of numerous patients. Bradley's subsequent
systematic trial of stimulant use for the alteration of behavior noted
"remarkably improved school performance." This groundbreaking study
inspired many subsequent studies of stimulants and changed the treatment of
what is known today as ADHD25.
Treatment of ADHD with psychostimulants, such as methylphenidate
(brand name Ritalin) and mixed amphetamine salts (brand name Adderall),
has been proven effective for ADHD symptom reduction.4,6,9,26-29 These
stimulant medications affect dopamine and norepinephrine reducing
inattention, impulsivity, and hyperactivity. Though side-effects such as
increased heartrate and blood pressure, tics, insomnia, and agitation may be
bothersome, the evidence suggests stimulants are safe for chronic use in
children older than four years.23,29 A few studies have shown treatment
benefits in meaningful endpoints like academic success.13,14,30 Relative to
behavioral therapy, ADHD medication has been shown to be cost effective in
symptom reduction and more cost-effective than behavior therapy alone.26,31-33
The main non-stimulant treatment for ADHD is atomoxetine. This nonstimulant may be preferable for children with ADHD and certain comorbidities,
such as comorbid anxiety disorder, substance abuse disorder, and tics.5,34,35
There are a variety of formulations of the stimulant medications which
differ primarily in their duration of effect. Immediate release (IR) stimulants
may last 3-4 hours and require multiple daily doses, whereas sustained
release (SR) stimulants may last upwards of 12 hours and have a longer
3

duration of effect and slightly different modes of delivery, factors which may
contribute to slight improvements in adherence.36 For instance,
lisdexamfetamine (brand name Vyvanse) is an SR stimulant pro-drug which
requires lysine cleavage in the red blood cells to become the active
dextroamphetamine. Thus, lisdexamfetamine has both a long duration of effect
and has a reduced potential for abuse, offering a contrast with mixed
amphetamine salt which is racemic and not in ingested in a pro-drug form.
Stimulants have their drawbacks, however, as they may cause sideeffects including increased heartrate and blood pressure, decreased appetite
and trouble sleeping.37 The use of IR medication may lead to uncomfortable
dose peaking with increases in adverse effects, increased inconvenience of
multiple daily doses, and a lower adherence rate relative to extended release
stimulants38. Since the introduction of SR medication formulations, such as
long-acting methylphenidate (brand name Ritalin-LA) in 2002 and extendedrelease mixed amphetamine salts (brand name Adderall XR) in 2001, SR
formulation use has increased.39 This trend may be due to improved drug
adherence, patient convenience, and lower peak and higher trough dose
concentrations relative to IR formulations. Therefore, patients on SR
medications may have more comfortable dose peaking and improved
adherence.40-43 Suffice to say, as our understanding of ADHD has grown, so
too has the number of ADHD drugs, with over twenty medications and
formulations approved by the FDA for treatment of ADHD.
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While prescription of these SR formulations may yield improvements in
adherence, some SR formulations may be more expensive than IR
formulations. Considering formulation price differences, there may be
sociodemographic disparities in the prescription of these more expensive
formulations. One 2013 study of Florida Medicaid claims found no racial
disparity in SR medication prescriptions.36 However, due to a limited and nongeneralizable sample, this study was not applicable to the American
population at large. Further, although numerous studies have compared the
proportions of any medication use in different racial or socioeconomic groups,
we have not identified any studies of factors associated with SR versus IR
prescription in nationally representative data derived from medical charts
versus information recall.4,14,41,43,44
Our cross-sectional analysis and predictive modeling of ADHD
medication prescriptions may be a useful addition to this literature. While one
previous study provided useful information on the prevalence of ADHD
diagnosis and medication prescription, no published NAMCS study has built a
predictive model of SR treatment.45 Furthermore, the majority of medication
treatment studies in other data sources did not examine predictors of specific
types of medication prescription. Finally, there are few studies in the literature
of predictors SR vs IR stimulant prescription and those few studies of
medication type used limited regional datasets to make predictions.38,43
To address these evidence gaps, the purpose of this study was to
identify predictors of SR versus IR stimulant prescription in the United States.
5

To do so, we conducted a cross-sectional observational study of a nationally
representative survey of 2012 physician office visits. Our research question
was whether or not there are sociodemographic predictors of SR versus IR
stimulant prescription in the US pediatric population. Potential predictors were
identified from a set of sociodemographic covariates including age, sex, pay
type, office region, race, and physician specialty. This analysis was strong in
its national generalizability, up-to-date data source, and use of multivariate
modeling for adjustment of odds ratios. While our study had limitations due to
a lack of patient-level data in the NAMCS and due to the relatively small
pediatric ADHD sample present in the 2012 data, we are confident our findings
will be a useful piece of evidence for prescribing patterns in the United States.
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CHAPTER 2

LITERATURE REVIEW
Literature Review
Methods for Literature Search
To ensure this project targeted specific evidence gaps related to SR
medication treatment disparities in childhood ADHD, a thorough literature
review was conducted with the PubMed Medical Subject Heading system
(MeSH) terms: ("Attention Deficit Disorder with Hyperactivity/drug therapy")
and ("healthcare disparities" OR "epidemiology" OR "Delayed-Action
Preparations"). To ensure our search examined only childhood ADHD (ages 417), the PubMed filter "Child" was utilized. We chose to search the literature
from January 1987 to September 2015 because throughout this period,
hundreds of studies have been published while subtle changes occurred in the
DSM III-R in 1987, the DSM IV in 1994, and the current DSM-V, published in
2013. The year 1987 was an appropriate starting date for our search since that
year the disorder title was changed from ADD to ADHD and there was more
robust empirical validation of diagnostic criteria.
From over 10,000 study titles reviewed in the literature search, 33
articles relevant to this study of sustained release medication disparities were
included (Figure 1). From 10,000 titles, studies of adults, genetics,
neuroimaging, historical analyses, editorials, opinions, and commentaries
7

were excluded. The abstracts of approximately 500 relevant abstracts were
reviewed for inclusion. After abstract review, 360 were excluded due to
utilizing adult populations, performing a different type of study, or being a
duplicate abstract. The full text for each included study was acquired to
determine the evidence base on sustained release disparities.
While numerous studies were included on the background of ADHD
prevalence, diagnosis, and treatment, many were excluded due to lack of
relevance to predictors of medication prescription. Moreover, several
prevalence studies and meta-analyses of these prevalence studies were
examined. We excluded any prevalence studies that did not analyze predictors
of medication treatment. Nevertheless, many of these articles on prevalence
trends have been useful in the establishment of the burden and impact of
ADHD and we include a small synopsis of this work in order to establish the
proper context for our work.
Literature Review
Trends in Treatment
While studies are not in agreement about trends in ADHD diagnosis
rates, there is a strong consensus that prescription medication use for ADHD
has increased in recent years. In 2007, in broadly representative regional and
national prescription benefit plans, Castle et al. determined that treatment
prevalence increased 11.8% for children and adults in the period 2000-200546.
They noted a particular increase in girls and adults. Also, this study found that
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ER became increasingly preferred over IR from 2000-2005 and that generic
use in children went down from 2000-2005. In 2012, Chai et al. found that
ADHD medication use increased 46% from 2002 to 2010 and that MPH was
the most prescribed medicine to adolescents (12-17)47. Furthermore, in 2014
Visser et al. found the prevalence of medicated ADHD increased by 28% from
2007-20117. Finally, Toh et al. in 2006 used the NAMCS 1993-2003 data and
found an increase of 2.1% to 4.0%45. Therefore, if we examine medication use
in the NAMCS in 2012, we might see the rate of drug mentions for childhood
ADHD in the range of 4% to perhaps as much as 8%, if increases are found to
be consistent with previous findings. These studies are generally in
agreement: ADHD medication use has become more frequent over recent
years. Most of these studies did not examine predictors for specific types of
medication, but were rather simple trend analyses. Therefore, another trend
analysis would not target evidence gaps.
Literature Review
Predictors of Treatment
We examined the literature regarding predictive factors associated with
ADHD diagnosis and treatment, including age, sex, race, insurance status,
and region. In 2012, Lingenini et al. found that depression, anxiety, type of
healthcare coverage, and male gender were all associated with ADHD
diagnosis48. To do so, they used the National Survey of Children's Health
(NSCH), which is a population-based cross-sectional survey collected via
digital-dialing of US households from 2007-2008. Their sample included
9

91,642 children and they found that roughly 10% of parents reported their
child had received a diagnosis at some point. Like the diagnosis, medication
use at any prior or current time was assessed via a survey question to
parents. Lingineni et al. found that, relative to white children, Black and
Hispanic children were less likely to be diagnosed (OR=0.72 and OR=0.65).
Numerous studies suggested ADHD differences in females, perhaps
due to the lack of hyperactivity and impulsivity symptoms in some girls with
ADHD. Froehlich et al. examined 2001-2004 NHANES data and found that
boys were more likely to be diagnosed.49 Furthermore, there may be varying
rates of care in groups of lower socioeconomic status and in different
racial/ethnic groups. In their 2007 study of 2001-2004 NHANES data,
Froehlich et al. utilized three different logistic regression models, including one
for medication treatment amongst those with ADHD by DSM-IV criteria. They
found that, relative to 8-11 year olds, 12-15 year olds were more than three
times likelier (AOR=3.6, 95% CI = 1.6-8.2) to take any medication in the past
year. Furthermore, they found that relative to white children, African-American
(AOR = 0.7, 95% CI = 0.4-1.6) and Mexican-American (AOR = 0.6, 95% CI =
0.2-2.0) children were less likely to have medication treatment. While this
study does have the strength of measuring prevalence with reported
symptoms, the small sample size (n=222) does not confer statistical
significance to odds ratios of treatment across sociodemographic groups.
Another study of the NHANES data by Merikangas et al. agreed with these
findings of prevalence and rates in subgroups17. Since the NHANES dataset
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only includes a survey question about any ADHD medication use in the past
year, these studies did not report type of medication used, whereas our study
will do so.
An earlier study in 2004 by Stevens et al had similar findings on ADHD
disparities as these NHANES studies. They found that ethnic and regional
differences existed in ADHD diagnosis for pediatric primary care visits.50
Relative to whites, Hispanics were less likely to be diagnosed and AfricanAmericans less likely to use medication. Symptomatic prevalence was higher
for poor children, whilst medication use was more likely in the wealthiest
children.
Another examination of race and medication use was published in 2006
by Zuvekas et al., which looked at trends in stimulant use and analyzed
stimulant use in sociodemographic subgroups.54 In their 2002 data source,
they found that females, blacks and Hispanics, and uninsured children had
lower proportions of stimulant use relative to respectively, boys, whites, and
those on private/public insurance. Furthermore, geographically the study found
slight regional differences in medication use in 2002, with the South (3.4%)
and Midwest (3.0%) having more use than the Northeast (2.7%) and the West
(2.2%).
While these previous studies examined diagnosis and any kind of
treatment, they didn't address SR or IR stimulant prescription specifically. In
2013, Saloner et al. published a highly relevant study to predictors of
sustained release ADHD medication use36. Their data source was claims data
11

and it was limited to Florida Medicaid 96-05. The authors found that ADHDdiagnosed minorities were less likely to utilize medication (unadjusted odds
anywhere from 18% less likely to 22% less likely depending on year and group
comparison). Amongst those who did use medications, they found AfricanAmerican and Hispanic children were not much less likely to use long-acting
medications than white children (unadjusted odds from 5% to 14% less likely
for African-Americans and 3 to 13% less likely for Hispanics).One limitation of
this study is it does not utilize a nationally generalizable, up-to-date study
population. For example, new medications/formulations were recently
released, which this data did not capture (e.g. Kapvay in 2010, Quillivant XR in
2012, and Azenys XR-ODT in 2016). Furthermore, Florida Medicaid data is
not necessarily indicative of the national population of American children.
Another study published in 2010 by Lang et al. primarily examined
trends in medication but which specifically looked at short-acting vs longacting ADHD medications from 1994-2003 with international pharmaceutical
claims data.39 They found that US medication expenditures for ADHD
increased 594% from 1994-2003 largely due to price increases from
expensive new treatments introduced in their study period. These analyses
demonstrated that only 1% of the rise in US expenditures was due to sales
volume, whereas 97% was due to price and 2% to residual. Therefore, we can
see a shift towards more expensive long-acting medications in the USA before
2012.
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In their 2013 study of UK data of 77 individuals aged 6-18, Gormez et
al. studied the effects of switching to MPH-SR from MPH-IR.51 They found that
some clinicians may consider using higher doses or an additional MPH-IR
dose to augment the effects of MPH-SR. They also supported the use of
specialist ADHD clinics, relative to generic service centers. This built upon the
2010 study by Thompson et al., which was a UK study that found amongst 97
patients, 32% responded poorly to the switch and in 26 of the 97 patients, SR
treatment was a failure and they were switched back.52 These studies highlight
the need for monitoring patients who switch from IR to SR medications.
Specifically regarding the superiority of SR vs IR stimulant formulations,
there have been a few studies on the question. In 2006, Steele et al.
conducted a randomized controlled effectiveness trial and found once-daily
formulations are more effective in multiple outcome measures including
remission rate53. In 2009, the Canadian Paediatric Society (CPS) put out a
position statement that suggests extended-release (XR) medications are
preferred over short-acting medications by both families and physicians.
Furthermore, these authors claim that XR preparations are expensive and
more unaffordable for disadvantaged populations.54 Along with this CPS
position statement, the NICE organization from the UK published guidelines on
ADHD that concluded modified-release medications are preferred over IR
medications because of convenience, improving adherence, different
pharmacokinetic profiles, reducing stigma, and reducing problems relating to
schools storing drugs (guideline 1.5.5.4).55 These three studies provided
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sufficient evidence that there are benefits for SR stimulant formulations,
relative to IR formulations. This body of work provides the crucial evidence to
support the central premise of our study, which is that SR may be slightly
better than IR and questioning if there are disparities in SR prescription.
In summary, this literature search identified the studies establishing the
advantages of SR over IR stimulant formulations and the studies highlighting
sociodemographic disparities in ADHD treatment. Therefore, since our study
purpose was to examine potential predictors of healthcare disparities in ADHD
medication treatment, our specific research question was whether or not there
were sociodemographic predictors of SR versus IR stimulant prescription in
the US pediatric population. Based upon our knowledge of previous literature,
we hypothesized that there may be sociodemographic predictors of SR vs IR
prescription including subgroups of age, sex, race, insurance status, and a
number of other potential predictors not addressed in previous studies.
Our study had strengths to build upon this previous literature, assessing
prescription patterns in a nationally representative sample and providing
adjusted odds ratios for sociodemographic predictors of prescription of
superior medication formulations. While potentially useful to ADHD treatment
decision-makers, our study limitations must be considered including a lack of
longitudinal data, a lack of utilization information, and smaller analytic sample
due to the use of only a single year of data. Nevertheless, our study may
provide valuable information in assessing sociodemographic disparities in
ADHD medication treatment.
14

CHAPTER 3

METHODS
Study Design
A cross-sectional study design was used, in which exposures and
outcomes are determined at the same point in time for a given population. This
study design allowed a broad analysis across many different levels of
variables, which will be useful for our study of pediatric ADHD treatment
disparities in the United States.
Methods
Sample
This study examined 2012 pediatric ambulatory care visits with an
ADHD diagnosis in the National Ambulatory Medical Care Survey (NAMCS).
The NAMCS a nationally representative survey distributed by the Center for
Disease Control (CDC). In the NAMCS, the basic unit of observation is the
physician office visit; therefore the study population is only representative of
those who visited physician offices. This data was generated by physicians
recording information about office visits in a randomly assigned week on a
survey form.
This data includes numerous variables including diagnoses, medication
codes, procedure codes, and sociodemographic variables. Diagnoses are
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indicated by the International Classification of Diseases (ICD-9) diagnostic
codes. Medication codes, including those for generic and brand name drugs,
do not indicate prevalent use, incident use, or drug switching, nor dosage or
actual drug utilization. Sociodemographic information is encoded in categorical
variables, though there may be numerous missing values including race in
32.9% of visits. The NAMCS does provide weights, strata, and cluster
information so that SAS 9.3 can produce nationally representative estimates of
sociodemographic information.
In the 2012 NAMCS there were a total of 76,630 unweighted visits and
928,629,953 weighted visits. There were 8,694 unweighted visits and 105,
548,504 weighted visits with an age of 4-17. We applied inclusion criteria to
create a study sample of pediatric ADHD visits with stimulant prescription
(Figure 2). Our analytic sample was constructed as follows:
1) Visits with an age between 4 and 17 and with an ICD-9 code of 314.0,
314.00, or 314.01 were included as the pediatric ADHD visit population.
2) Medication information was identified by medication codes and drug ID
codes, identified in the appendices.
a. Visits with Adderall XR, Ritalin LA, Focalin XR, Methylin-ER, RitalinSR, and Vyvanse were included in the SR group of interest.
b. Those with only Ritalin, Focalin, Adderall, Methylin, or
Methamphetamine were included in the IR reference group.
c. Those with a combination of IR and SR mentions will be considered
as SR, thus our model will compare "Any SR" vs." IR Only"
16

d. Those with a generic code for methylphenidate or mixedamphetamine salt combo were included as IR.
With these pediatric ADHD stimulant visits, we conducted a crosssectional study to determine any sociodemographic factors associated with
sustained release (SR) versus immediate release (IR) stimulant prescriptions.
Methods
Descriptive Statistics
Descriptive statistics were used to characterize the study population by
frequency and percentage. These analyses examined all pediatric visits with
an ADHD diagnosis as well as those visits with certain types of medication
prescribed like non-stimulants, SR, and IR stimulants. We used standard
NAMCS nationally representative weighing procedures to calculate medication
treatment in the independent variables including age group, sex, insurance
status, office region, race, and physician specialty. We also included
comorbidities relevant to ADHD, including obesity56, asthma15, anxiety5,
depression48, or autism.57 While these comorbidities were examined in our
descriptive statistics, they were not included in our modeling approach since
the research question for this study specifically targeted sociodemographic
disparities.
The national weighing process in the NAMCS utilized information on the
data cluster, data stratum, and patient weight for each NAMCS observation.
Cluster and strata adjustments are necessary due to the complex multi-stage
17

sample design of the survey. These design variables in the NAMCS allow for
creation of nationally representative estimates with appropriate variance
estimation for surveys. A priori power analyses were not conducted since
these statistical tests utilized readily available data entries.
To compare treatment proportions in population subgroups, we used
basic statistical tests of difference. To test for differences in the proportion of
SR stimulant used across different values of categorical variables, the
Pearson Chi-square (χ2) test or Fisher's exact test was utilized, if the
assumptions for the χ2 were not met. The question for each independent
variable was whether or not proportions of that variable differed significantly
for those with SR vs. those with IR. While independent variables related to
diagnoses were dichotomous, for the independent variables, including race,
pay type, age group, physician specialty, and office region, overall p-values for
the entire variable were assessed. For the only continuous variable, age, a ttest was used to determine if SR medication prescription has a relationship
with age.
For all descriptive analyses, the 2-tailed alpha level of significance was
set at 0.05. All statistical tests were conducted using SAS 9.3 (SAS Institute
Inc., Cary, NC, USA).
Methods
Multivariate Regression Modeling

18

To address the evidence gap regarding the predictors of SR ADHD
medication prescription, we utilized a predictive logistic regression modeling
approach. This method allowed us to examine the associations between the
dependent variable, SR stimulant prescription, and the predictors of interest
including sex, age, racial and ethnic background, geographic region, pay type,
and physician specialty. For each predictor of interest, our logistic regression
model produced adjusted odds ratios comparing the relative likelihood of SR
stimulant prescriptions vs. those with only IR prescriptions. We constructed
both an initial multivariate model and we sequentially removed variables using
an iterative, manual process to remove covariates that are not predictive of SR
vs IR stimulant prescription. This reduced model was compared to the larger
initial multivariate model using the AIC, c-statistic, and the Hosmer-Lemeshow
test in order to assess model fit.
An initial multivariate logistic regression model was built using the first
univariate associations, then assessing multi-collinearity of selected
variables.58 Univariate tests of association were conducted between the
dependent variable, (i.e. type of medication prescribed [SR vs IR]), and the
independent variables, potential sociodemographic predictors. A parametric
assessment was conducted to assess the continuous variable "Age" for
possible creation of an age category variable (see appendix for assessment).
Potential predictor variables with a univariate test p-value of <0.15 were
candidates for multivariate model inclusion59. Multicollinearity was assessed
for this model and all condition indices being less than 30 and variance
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inflation factors being less than 8, multi-collinearity was not an issue for this
data.
To refine this initial model, an iterative, manual process of backwards
elimination was used to remove variables that do not contribute to the
prediction of the mention of SR vs IR. Variables with a Wald p-value
assessment of p>0.10 were excluded and the AIC was examined – a lower
AIC meaning a better fitting model. Furthermore, the c-statistic was examined
for each model, with a preferable range of 0.6-0.8 for a model but 0.5 being
the minimum accepted value. Goodness of fit was tested using the HosmerLemeshow test, wherein a non-significant value (p>0.05) shows the model to
be a good fit. Using multiple model fit tests ensured our multivariate logistic
regression models of SR vs IR prescription were aptly fit to the data.
Equation 1 defines the general equation of multiple logistic regression:
π(x)

Eq1: g(x) = ln (1−π(x)) = 𝛼 + 𝛽1 𝑥1 + 𝛽2 𝑥2 + ⋯ + 𝛽𝑝 𝑥𝑝
Equation 2 defines the logistic regression model that was used:
Equation 2:
y     1age   2 Sex   3 race   4 Insurance   5Specialty

  5 Region  

Where y is the probability of having SR stimulant treatment, α is the
intercept, and the β’s are the coefficients on the independent variables and ε is
standard error. If analysis indicates that significant interactions exist between
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variables, they were added to the model. To interpret our odds ratios (OR), an
OR higher than 1 indicates higher odds of having SR treatment, for example
an OR of 1.2 means 20% higher odds of having SR treatment.
The independent variables we investigated for inclusion in our model
consist of the sociodemographic information available in the NAMCS (see
appendix). The main divisions of race/ethnicity were African-American,
Hispanic, Other, and White. Regarding insurance status, we examined
Medicaid, Self-Pay, and other groups against Private Insurance. Age grouping
via parametric assessment was considered, since clinical guidelines vary for
those younger than 6 compared to 6-11 year olds and 11-17 year olds. There
were numerous categories of physician specialty; however, the only values
with sufficient sample size were General/Family physician, Pediatrician,
Psychiatrist, and Neurologist.
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CHAPTER 4

RESULTS
Our study purpose was to examine potential predictors of healthcare
disparities in ADHD medication. First, we used descriptive statistical analysis
to answer the question of whether there are different proportions of medication
prescription in different population subgroups. Then we built a logistic
regression model to assess whether there are predictors of the prescription of
SR vs IR stimulants. These two analyses were targeted to build upon previous
literature and shed light on ADHD treatment evidence gaps.
Results
Sample characteristics
Out of a total of 928,629,953 office visits in 2012 and 105,548,504
(11.37%) visits with an age of 4-17, we found 7,088,227 (7.56%) had one of
the two diagnosis codes for ADHD (ICD-9: 314.00, 314.01). After applying our
study inclusion criteria, we selected a total of 4,617,709 (65.15%) pediatric
visits for our study of stimulant medication prescription. The majority of
selected visits mentioned sustained release (SR) stimulant (n=3,431,741,
74.32%) while the minority mentioned only immediate release (IR) stimulant
(n=1,185,968, 25.68%). There were 2,268,862 visits (32.01%), with a
combination of SR/IR which we included as "SR" in our analyses.
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Regarding medications taken in the general childhood ADHD
population (n=7,088,227), we found that 5,475,854 visits (77.25%) had a
mention of any ADHD drug (stimulants or non-stimulants) (Table 1). SR
stimulants were prescribed for 3,886,395 visits (54.83%), while IR stimulants
were prescribed for 3,904,438 visits (55.08 %), and 2,540,260 had codes for
both SR and IR stimulants (35.84 %). The most common drugs included
methylphenidate extended-release (brand name Concerta, n=1,551,329,
21.89%), lisdexamfetamine (n=1,395,967, 19.69%), and dexmethylphenidate
(n=786,221, 11.09%). Methylphenidate of any sort was prescribed in
approximately one third of pediatric ADHD visits (n=2,444,725 (34.49%). The
brand version Adderall was frequently prescribed (n=434,082, 6.12%), as was
the generic code mixed amphetamine salts (n=781,624, 11.03%). A small
minority of visits had a mention of a non-stimulant medication for ADHD
(n=858,145, 12.11%), including mentions of atomoxetine (n=178,195, 2.51%),
guanfacine (n=343,206, 4.84%), and clonidine (n=385,038, 5.43%).
Results
Demographics of SR and IR Medication Groups
To examine the SR or IR stimulant prescription study population that
was used in the logistic model, we performed chi-square tests between each
of the independent variables and our dependent variable, SR prescription
(relative to IR only prescription). We found statistically significant associations
between SR prescription and pay type, office region, anxiety, and autism
(Table 2). The logistic model study sample, 421 unweighted visits, comprised
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of those visits with either SR or IR medication. Of these 421 visits, 313 had SR
prescription representing 3,431,741 weighted visits (74.35%). In this sample,
there was roughly a 3:1 ratio of males to females (2,508,268 vs. 923,473) and
males had a non-significantly higher rate of SR prescription (76.46% vs.
69.05%, p=0.23). There was also a non-significant difference between the 4-6
age group (n= 163,120, 54.92%) and the 7-11 age group (n= 1,744,109,
73.50%) and the 12-17 group (n= 1,524,512, 78.27%, p=0.09). Relative to
white children, who had the lowest rate of SR prescription (n=2,220,275,
71.11%), children with a race of Black (n= 669,357, 80.59%) and Hispanic
race (n=498,270, 80.70%) and "Other" race (n=43,838, 92.62%) had slightly
higher proportions of SR prescription.
Regarding payment type, the few self-pay visits had a significantly
lower rate of SR prescription (n=105,146, 59.24%), whereas the private
insurance (n=1,834,308, 79.75%) and Medicaid (n=1,227,480, 77.93%,
p=0.01). populations had significantly higher proportions of SR prescription.
The Southern region had significantly more SR prescriptions (n=1,697,891,
80.94%) whereas the Midwestern (n=850,702, 71.54%) and Northeastern
(n=400,037, 76.22%) regions had lower rates and the Western region had the
lowest rate of prescriptions (n=483,111, 59.95%, p=0.05). Finally, there was a
significantly larger proportion of SR prescription in those with a comorbid
anxiety disorder (n=154,062, 90.34%, p=0.01) than those without anxiety.
Furthermore, there was a significantly low rate of SR prescription in the very
few cases of comorbid ADHD and autism (n=805, 3.22%).
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Results
Multivariate Logistic Regression
To begin our logistic regression, we performed univariate logistic
regression between presence of the dependent variable (SR vs IR only) and
the independent variables, including sex, age group, race, pay type, office
region, and physician specialty (Table 3). We found five significant univariate
predictors of SR prescription relative to IR prescription, including age group,
race, office region, payment type, and physician specialty. Significance was
determined by the Wald Chi-square P-value threshold of P=0.15, considering
individual levels of categorical variables. Regarding age, we conducted a
parametric assessment and decided to treat this variable as a categorical
variable in three groups (see Appendix D for parametric assessment).
Once we determined the univariate predictors to include, we ran an
initial multivariate logistic regression model to attempt to predict SR vs. IR
(Table 4). Examining the adjusted odds ratios and their 95% confidence limits,
we see no covariate with confidence limits not including the value 1. This
indicates that amongst these sociodemographic variables in the 421
unweighted visit sample in the 2012 NAMCS, there are perhaps only nonsignificant predictors to assess. For example, regarding age grouping, we see
that when compared to those aged 7-11, those 12-17 are 1.69 times more
likely to have SR prescription (versus IR) and (OR=1.691, 95% CL: [0.795,
3.595]) and those aged 4-6 are almost 3 times less likely to receive SR versus
IR (OR=0.359, [0.131, 0.985]). Relative to visits with a white race/ethnicity,
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those with Black race (OR=2.183, [0.777, 6.134]), Hispanic race (OR=2.223,
[0.457, 10.819]), and "Other" race (OR=2.717, [0.397, 18.611]) are all nonsignificantly more likely to have SR versus IR only prescription. Relative to
visits with a general or family practitioner, those with pediatricians (OR=1.725,
[0.644, 4.618]), psychiatrists (OR=1.773, [0.590, 5.328]), and neurologists
(OR=1.183, [0.397, 3.527] were all non-significantly more likely to prescribe
SR vs IR only. Relative to the Northeast region, the Midwest (OR=0.794,
[0.317, 1.991]) and the West (OR=0.684, [0.197, 2.370]) were less likely to
prescribe SR versus IR while the South (OR=1.351, [0.507, 3.597]) was more
likely to prescribe SR versus IR. Finally, relative to those with private
insurance, visits with Medicaid/CHIP (OR=0.823, [0.335, 2.020], Self-Pay
(OR=0.286, [0.060, 1.372]), and "Other" payment (OR=0.598, [0.115, 3.107]
were all less likely to prescribe SR versus IR stimulants.
Regarding model fit, since proc surveylogistic does not have the ability
to conduct the Hosmer-Lemeshow test, we examined the AIC, the C-statistic,
and we constructed an identical initial model with proc logistic. The survey
methods and non-survey methods produce the same odds ratio point
estimates for predictors, however the survey methods produce a wider
confidence interval for these estimates. We then tested the non-survey model
fit with a Hosmer-Lemeshow goodness of fit test and found a properly
specified initial model (p=0.1954) (see Appendix E).
When attempting to construct a reduced multivariate model that would
have improved model fit, we were unable to exclude any of these four
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categorical variables without worsening model fit. First, we manually selected
region to remove based upon its p-values being non-significant, however we
saw a decreased C-statistic from 0.663 to 0.648, an increased AIC from
4075966.2 to 4116137.9, and saw non-significant Hosmer-Lemeshow tests for
both models. This indicates that this model is not improved via the removal of
region. Similar analyses were conducted after cutting each of the other
variables, and in each case the C-statistic and AIC worsened while HosmerLemeshow remained non-significant. Therefore, the initial model is the best
and we do not present any final models here.
Results
Sensitivity Analysis
Since our model counted generic drug codes, including
"Methylphenidate" and "Amphetamine Salt Combo," as IR drugs and not SR
drugs, we conducted a basic descriptive analysis of generic drug codes. If
generic drugs are not counted as IR drugs, but rather excluded altogether,
then the count of IR drug codes decreases from 314 (73.67%) to 128
(29.52%). The two generic methylphenidate codes (n=29, 7.67% and n=193,
46.41%) and the Adderall generic code (n=64, 14.15%) are present in the
majority of ADHD visits. Therefore, if these codes were not included in our
model, we would see a large reduction in sample size. In the future, a full
sensitivity analysis of the logistic modeling will be conducted to assess the
effect of this medication coding decision.
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CHAPTER 5

DISCUSSION
Attention deficit hyperactivity disorder (ADHD) is a highly prevalent
mental health disorder in the United States and billions of dollars are spent on
ADHD treatments each year. Our study provides an important piece of
evidence which targets the paucity of information regarding the predictors of
prescription of sustained release (SR) versus immediate release (IR)
stimulants. In the current study, we have identified non-significant predictors of
SR vs IR prescription, including race, region, age group, physician specialty,
and payment type. While the 95% confidence limits for these adjusted oddsratios for all of these covariates included 1, we nevertheless can use these
results to state that there is no stand-out disparity in the prescription of SR vs
IR stimulants for pediatric ADHD in the United States.
After building our logistic models, we found that age group and race
were important predictors of SR prescription in office visits. The predictive
relationship between older age group and SR vs IR only prescription may arise
from the benefits of SR stimulants, including reduced stigma at school, less
potential for misuse, slightly improved adherence, or from the prioritization of
avoiding side effects such as agitation and anxiety. Regarding race, it is
interesting to note that while the odds of receiving SR vs IR were over twice as
great in Black, Hispanic, and Other race when compared to White race, there
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is a chance these odds are 1. Further study with multiple years of the NAMCS
dataset may provide a larger sample to reduce the variance of the 2012 data.
Furthermore, in this initial multivariate model, we found that physician
specialty, payment type, and office region were non-significant predictors of
SR vs IR only. While pediatricians and psychiatrists may be 1.7 times more
likely to prescribe SR vs IR only, it is also possible these values are close to 1.
Further, though private insurance is more likely to prescribe SR vs IR only
than all of the other payment types, once again there are non-significant
intervals for Medicaid, Self-Pay, and Other. Lastly, though the South may be
most likely to prescribe SR vs IR only, and the Midwest and West the least
likely to prescribe SR vs IR only, these odds ratios are fairly close to 1 as well.
In summation, though our models did not necessarily support the argument
that SR stimulants are prescribed differently in varying sociodemographic
groups, numerous non-significant odds-ratios were identified which may point
towards a measurement of disparity if a larger sample size was used to build
the model.
Due to these negative findings, we were unable to confirm many
previously studied disparities in ADHD medication prescription. This may be
indicative of improvement in prescribing patterns and equal access for those in
minority groups. Furthermore, since the sampling frame for our study is shifted
to 2012, it is possible that new diagnostic criteria, medication options, or
increased awareness may be different from earlier study sample frames.
Lastly, covariates that were important in previous studies, such as sex and
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ADHD subtype, were not found to be significantly associated with SR vs IR
only prescription. Therefore, though we did not find stark evidence of
disparities in SR prescription, these null findings are a useful piece of evidence
and may encourage further consideration of ADHD healthcare disparities.
Our study brings useful evidence to the scholarly discussion of SR vs
IR stimulant prescription. While other studies have conducted somewhat
similar analyses of SR vs IR, our study was the only nationally representative
comparison of IR and SR medication prescription with logistic modeling
approaches. Though Lingenini et al. had a relevant comparison of IR and SR,
their dataset was from Florida insurance claims alone. Furthermore, while Toh
et al. studied stimulant prescriptions in the NAMCS, they did not use the most
recent data set and their statistical analysis was limited to descriptive
statistics. Therefore, our study provides a set of nationally representative nonsignificant predictors which may guide ADHD decision-making. This may aid in
optimizing care, highlighting differences in type of medication prescription in
different sociodemographic groups, and examining how to reduce mental
healthcare disparities in the United States pediatric population.
Combining the findings of our study and previous studies, there still
remains an evidence gap regarding national trends in ADHD medication use.
We could expand the current analysis of 2012 SR vs IR prescription by
comparing non-stimulants to stimulants and comparing these with visits with
no drug use. Furthermore, one might utilize a more recent year than 2012,
multiple years of data, or a data source that contains patient-level longitudinal
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data. Finally, one could expand the current analyses by incorporating multiple
years of the NAMCS that pre-date 2012. These future analyses would all be
complementary to the present study with some of its limitations.
Discussion
Limitations
There are a few limitations to this study. First, cross-sectional study
designs are not able to follow patients over time, thus we do not have
indications of incident vs prevalent use or a change in medication status.
Despite this limitation, our study design examined a large, nationally
representative data set to draw conclusions about predictors of current
medication status in office visits.
One potential issue with survey data and medication coding, however,
is that a survey of ADHD medication prescriptions may be prone to
misclassification errors. In filling out a survey, a physician may mistakenly
classify a prescription of an SR stimulant like Adderall XR as simply Adderall,
which we would then reduce the magnitude any potential differences in the
two groups. This misclassification is one example of the fallibility of physician
reporting in surveys.
Another medication coding issue is the assumption in our model that
generic drugs represent IR prescriptions, not SR prescriptions, though
generics could potentially refer to either an IR or SR formulation. To examine
the frequency of these generic drugs, we conducted a descriptive statistical
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analysis and found that generic codes are present in over 60% (n=286) of our
study sample visits. Though we assume these 286 visits all have IR
prescriptions, it is possible some fraction was actually referring to SR
prescriptions. To address this uncertainty, future analyses should conduct a
full sensitivity analysis by producing logistic model with verified IR and SR
codes via brand-name drugs.
Our current results will be generalizable only to the American pediatric
population that visited physicians' offices in 2012. Therefore, this data is not
necessarily representative of the American pediatric population at large, since
different sociodemographic groups may have differing likelihoods to visit a
physician's office. Our estimates of prevalence and drug utilization may have
been lower than the true population levels, since previous studies have
demonstrated lower estimates in ICD-9 based studies. Prescription of ADHD
medication was measured by drug codes in a cross-sectional study design,
which could not take into account adherence, persistence, or differentiate
between prevalent and incident medication use. Finally, some confounding
variables were not present in our data set, including socio-economic status,
severity of ADHD symptoms, or previous medication therapy. Therefore, our
logistic model could not adjust for these unmeasured confounders.
Despite these limitations, our dataset and methods allowed us to target
existing evidence gaps and to expand the evidence base for decision-makers.
Since few studies have identified predictors for SR stimulant prescriptions, and
none in a nationally representative dataset, our analyses may provide useful
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evidence about prescribing patterns for pediatric ADHD. Specifically, we have
shown that there is not stark evidence for sociodemographic disparities in the
prescription of SR vs IR stimulants for ADHD in the United States in 2012.
While our evidence may point towards some disparities, due to a small sample
size and perhaps high variance data, we were unable to find significant
predictors of SR vs IR prescription use.
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CHAPTER 6

CONCLUSION
In this 2012 sample of physician office visits, we selected a study
population of 4,617,709 pediatric ADHD visits with prescriptions of SR or IR
stimulant. After conducting a logistic predictive model, we did not find
significant sociodemographic predictors of SR vs IR prescription. First, we did
not find that subtype of ADHD or sex were significant univariate predictors of
SR vs IR prescription. Nevertheless, relative to 7-11 year olds, we found a
non-significantly higher likelihood of SR vs IR stimulant prescription in those
aged 12-17 (OR=1.691, 95% CL: [0.795, 3.595]) and a lower likelihood in
those aged 4-6 years old (OR=0.359, [0.131, 0.985]). Non-white race nonsignificantly increased likelihood of SR vs IR prescription by a factor of two,
while those without private insurance were non-significantly less likely to have
SR vs IR. These non-significant odds ratios may have been due to the
changing patterns of treatment or to the varying methods to measure ADHD
treatment.
These analyses did not identify any strong sociodemographic predictors
for SR versus IR stimulant drug prescription. This is a positive and noteworthy
result especially when considering this study utilized a recent year of data that
was nationally representative. While many other studies found disparities in
sociodemographics, some were in older data sources and some were not
nationally representative. Therefore, our findings may be helpful for assessing
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the current state of American ADHD treatment. With this knowledge,
practitioners and policy-makers may move forward with slightly more detailed
evidence to guide future ADHD decision-making.
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Table 1. Characteristics of Pediatric ADHD Visit Population
Characteristic
Frequency Weighted Frequency

Percent

All Pediatric ADHD Visits
Female
Male
4 to 6 years old
7 to 11 years old
12 to 17 years old
Private Insurance

711
190
521
68
335
308
325

7,088,227
1,932,532
5,155,695
668,010
3,374,121
3,046,097
3,427,928

100.00
27.26
72.74
9.42
47.60
42.97
48.36

Medicaid/CHIP
Self Pay
Other Payment Type
White Race
Black Race
Hispanic Race
Other Race
Northeast Region
Midwest Region
South Region
West Region
General and Family
Practitioner
Pediatrician
Psychiatrist
Neurologist
ADHD Primarily Inattentive
ADHD Combined Type
Depression
Anxiety
Autism
Asthma
Obesity
Any ADHD Drug
Combination SR/IR
Immediate Release
Adderall
Adderall Generic
Methylphenidate
Dextrostat
Dexmethylphenidate
Sustained Release
Adderall XR

272
36
23
486
120
78
27
87
200
291
133
91

2,473,735
321,547
249,713
4,771,295
1,229,675
956,710
130,547
912,679
1,786,761
3,221,211
1,167,575
1,133,772

34.90
4.54
3.52
67.31
17.35
13.50
1.84
12.88
25.21
45.44
16.47
16.00

299
277
32

3,715,065
1,730,501
393,403

52.41
24.41
5.55

132
579
73
62
9
51
20
538
250
379
44
81
234
4
73
375
36

1,511,043
5,577,184
664,730
348,965
80,894
601,921
249,534
5,475,854
2,540,260
3,904,438
434,082
781,624
2,444,725
27,753
786,221
3,886,395
342,147

21.32
78.68
9.38
4.92
1.14
8.49
3.52
77.25
35.84
55.08
6.12
11.03
34.49
0.39
11.09
54.83
4.83
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Vyvanse
Daytrana
Ritalin SR
Ritalin LA
Metadate CD
Methylin ER
Concerta
Focalin XR
Non-stimulants
Guanfacine
Clonidine
Atomextine

134
11
2
1
7
3
157
30
117
44
59
20

1,395,967
95,483
40,731
3,003
80,956
22,866
1,551,329
387,330
858,145
343,206
385,038
178,195

19.69
1.35
0.57
0.04
1.14
0.32
21.89
5.46
12.11
4.84
5.43
2.51

Table 1. Characteristics of Pediatric ADHD Visit Population. This sample of ADHD visits
includes those visits with patients aged 4-17 and with ICD-9 diagnosis codes used for ADHD:
31400 and 31401.
Acroynms Used: CHIP= Children's Health Insurance Program; SR = sustained release;
IR=immediate release; ADHD= Attention Deficit Hyperactivity Disorder; LA=long acting;
ER=extended release; XR=extended release;
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Table 2. Comparison of Characteristics of Visits with Sustained Release versus
Immediate Release Stimulants
Demographic
Sample (IR
Freq of Wtd Freq
Pr >
Group
and/or SR)
SR Rx
of SR Rx
% SR Rx
ChiSq
421
313 3,431,741
74.35
Study Sample
Sex
0.23
119
83
923,473
69.05
Female
302
230 2,508,268
76.46
Male
Age Group
0.09
31
19
163,120
54.92
4 to 6
212
152 1,744,109
73.50
7 to 11
178
142 1,524,512
78.27
12 to 17
Pay Type
0.01
205
161
1,834,308
79.75
Private Insurance
153
116 1,227,480
77.93
Medicaid/CHIP
20
11
105,146
59.24
Self Pay
9
5
92,915
67.84
Other
Race / Ethnicity
0.30
292
207 2,220,275
71.11
White
70
56
669,357
80.59
Black
48
41
498,270
80.70
Hispanic
11
9
43,838
92.62
Other
Office Region
0.05
53
39
400,037
76.22
Northeast
127
94
850,702
71.54
Midwest
168
134 1,697,891
80.94
South
73
46
483,111
59.95
West
ADHD Subtype
0.68
77
54
697,115
72.19
ADHD PI
344
259 2,734,626
74.88
ADHD CT
Physician Specialty
0.41
General and Family
62
40
556,497
65.83
Practice
193
144 1,929,855
75.38
Pediatrics
134
104
684,297
78.51
Psychiatry
23
17
184,340
75.03
Neurology
Comorbidities
Depression
38
31
288,112
80.03
0.55
Anxiety
26
21
154,062
90.34
0.01
Autism
4
1
805
3.22 <.0001
Asthma
29
21
306,956
77.05
0.75
Obesity
10
8
140,910
71.25
0.86
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Table 2. Comparison of Characteristics of Visits with Sustained Release versus Immediate
Release Stimulants. This study population includes those with either an IR stimulant or SR
stimulant drug prescription, combinations were included as SR. The chi-square test was used
to compare proportions across groups. These study subgroup estimates are nationally
representative, calculated in SAS 9.3 via proc surveyfreq.
Acronyms Used: CHIP= Children's Health Insurance Program; SR = sustained release;
IR=immediate release; ADHD= Attention Deficit Hyperactivity Disorder; Rx=prescription;
PI=primarily inattentive; CT=combined type.
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Table 3. Univariate Logistic Regression Predicting Sustained Release
Prescription with Potential Sociodemographic Predictors
Analysis of Maximum Likelihood Estimates
Odds Ratio Estimates
Wald
95% Wald
ChiPoint
Confidence
Parameter
Estimate Square Pr > ChiSq Estimate Limits
0.3758 1.2146
0.2704
1.456 0.746 2.841
Sex Female (vs Male)
-0.8233
2.7648
0.0964
0.439 0.166 1.159
Age 4-6 (vs 7-11)
0.2613 0.6100
0.4348
1.299 0.674 2.502
Age 12-17 (vs 7-11)
------Race (ref=White)
0.5231 1.2173
0.2699
1.687 0.666 4.273
Race Black
0.5301 1.0986
0.2946
1.699 0.631 4.579
Race Hispanic
1.6293
3.4251
0.0642
5.1 0.908 28.637
Race Other
Pay type (ref=Private
------Insurance)
Pay type
-0.1089 0.0822
0.7743
0.897 0.426 1.888
Medicaid/CHIP
0.4832
0.536 0.094 3.066
Pay type Other -0.6242 0.4917
-0.9967
1.8156
0.1778
0.369 0.087 1.573
Pay type Self
Physician Specialty
------(ref=Gen/Fam)
0.4630 0.9959
0.3183
1.589 0.640 3.945
Pediatrics
0.6396 1.8444
0.1744
1.896 0.753 4.772
Psychiatry
0.4445
1.0774
0.2993
1.560 0.674 3.611
Neurology
Region
------(ref=Northeast)
-0.243 0.2645
0.607
0.784 0.311
1.98
Region Midwest
0.2814 0.3618
0.5475
1.325
0.53 3.314
Region South
-0.761 2.1498
0.1426
0.467 0.169 1.292
Region West
0.1383 0.1566
0.6923
1.148 0.579 2.277
ADHD CT (vs ADHD PI)
1.2044 5.5133
0.0189
3.335
1.22 9.113
Anxiety Disorder
0.162 0.0764
0.7823
1.176 0.373
3.71
Asthma
0.3509 0.3627
0.547
1.42 0.453
4.45
Depression
0.8643
0.85 0.132 5.464
Obesity -0.1622 0.0292
Table 3. Univariate Logistic Regression Predicting Sustained Release Prescription with
Potential Sociodemographic Predictors. We assessed the univariate association between
demographic characteristics of visits with SR drug prescriptions, relative to IR only. The
reference group for comorbidities was those who did not have that comorbidity. For
instance, the odds for SR prescription for those with anxiety disorder were compared to the
odds of those without anxiety disorder.
Acronyms Used: CHIP= Children's Health Insurance Program; SR = sustained release;
IR=immediate release; ADHD= Attention Deficit Hyperactivity Disorder; Gen/Fam= General
and Family Practitioner; PI=primarily inattentive; CT=combined type.
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Table 4. Initial Multivariate Logistic Model of Sustained Release vs. Immediate
Release Stimulant Prescription
Analysis of Maximum Likelihood Estimates
Odds Ratio Estimates
Wald
Freq
ChiPr > Chi Point
Parameter
in SR Estimate Square Sq
Estimate 95% Wald C.L.
Intercept
0.2794 0.2033 0.6521
4-6 (vs 7-11) 212
-1.0246 3.9550 0.0467
0.359 0.131 0.985
12-17 (vs 7-11) 178
0.5253 1.8641 0.1721
1.691 0.795 3.595
RACE White 292
------RACE Black
70
0.7809 2.1952 0.1384
2.183 0.777 6.134
10.81
RACE Hispanic
48
0.7990 0.9794 0.3224
2.223 0.457
9
18.61
RACE Other
11
0.9994 1.0360 0.3087
2.717 0.397
1
REGION Northeast
(ref)
53
------REGION Midwest 127
-0.2304 0.2415 0.6231
0.794 0.317 1.991
REGION South 168
0.3006 0.3617 0.5475
1.351 0.507 3.597
REGION West
-0.3801 0.3592 0.5489
0.684 0.197 2.370
Pay type
(ref=Private Ins) 161
------Medicaid/CHIP
116
-0.1949 0.1810 0.6705
0.823 0.335 2.020
Pay type Self
11
-1.2508 2.4469 0.1178
0.286 0.060 1.372
Pay type Other
5
-0.5144 0.3743 0.5407
0.598 0.115 3.107
Physician Specialty
(ref=Gen/Fam)
40
------Pediatrics 144
0.5451 1.1769 0.2780
1.725 0.644 4.618
Psychiatry 104
0.5727 1.0408 0.3076
1.773 0.590 5.328
Neurology
17
0.1678 0.0906 0.7634
1.183 0.397 3.527
Table 4. Initial Multivariate Logistic Model of Sustained Release vs. Immediate Release
Stimulant Prescription. A multivariate logistic regression model was constructed using
covariates with a univariate association to SR prescription (relative to IR only). These study
subgroup estimates are nationally representative, calculated in SAS 9.3 via proc
surveylogistic.
Acronyms Used: CHIP= Children's Health Insurance Program; SR = sustained release;
IR=immediate release; ADHD= Attention Deficit Hyperactivity Disorder; Gen/Fam= General
and Family Practitioner; Freq=Frequency;
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Figure 1. Literature Search Overview

10,851 Titles
Reviewed

~500 Abstracts
Reviewed

EXCLUDED: ~10,000 Abstracts




Not population of interest (i.e children)
Not publication type of interest
Not study of epidemiology (genetics,
imaging, history)

EXCLUDED: 360 Abstracts (commentary,
opinions)





140 Full Texts
Retrieved and
Reviewed



Literature review of clinical
information
Small clinical sample studies
Studies of symptoms
Study of non-medication treatment
(behavioral or alternative)
Duplicate abstract

EXCLUDED: 107 articles after full-text review:



33 studies relevant to our question
about SR vs IR disparities in
different sociodemographic groups

Not population of interest
Not topic of interest

Figure 1. Literature Search Overview. We conducted a literature search with the
PubMed MeSH system to identify important articles related to stimulant use for
pediatric ADHD. Our literature search aimed to answer the question of whether or
not SR drugs are less likely to be used in certain subgroups, relative to IR drugs. After
removal of irrelevant articles, we found 33 studies in the literature which were
relevant to our question about predictors of sustained release stimulant use.
PubMed Search Terms: ("Attention Deficit Disorder with Hyperactivity/drug therapy")
and ("healthcare disparities" OR "epidemiology" OR "Delayed-Action Preparations"
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Figure 2. Study Sample Selection Flowchart

76,630 office visits in
2012 NAMCS

711 pediatric ADHD
office visits

EXCLUDED: ~75,917 visits
 Not children (n=67,936)
 No Childhood ADHD
Diagnosis (n=7,983)

EXCLUDED: 290 visits
 Non-stimulant use (n=117)
 No medication used (n=173)

421 pediatric ADHD
office visits with
stimulant mention

SR stimulant mention
(n=313)
Including Combination
SR/IR (n=181)

IR stimulant mention
(n=108)
(Reference Group for
Predictive Model)

Figure 2. Study Sample Selection Flowchart. To select visits for our study of predictors
of pediatric SR prescription in 2012, we first included pediatric and ADHD visits. Next,
we included visits with stimulant prescription, exclusive of those with concurrent
non-stimulant drug usage. This left us with two subgroups of ADHD visits to compare
in our logistic regression modeling.
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Appendix A: Variables of interest and codes in the 2012 NAMCS
Variable Title
NAMCS Variable
Possible Values
Diagnosis Code1, 2
DIAG1-DIAG3
314.00, 314.01
for ADHD (or
comorbidities)
Drug Entry Name /
Generic Name
Code3
Drug Entry Name /
Generic Name
Code
Type of Payment

MED1-MED10

00001-99227

DRUGID1-DRUGID10

d00000

PAYTYPER

Sex

SEX

1 Private Insurance
3 Medicaid/CHIP
5 self-pay
7 Other
1, 2

Race

RACERETH

1, 2, 3, 4

Age

AGE

000-099

Geographic Region

REGIONOFF

1= NE, 2= MW
3=S, 4=W

Weight Variables

Notes
.00=ADD no H,
thus IA
.01= ADD w H,
thus PH or CT
May be generic
name or drug
entry name
Is generic in all
cases and value
starts with "d"

1=Female
2=Male
White, Black,
Hispanic, Other
(IMPUTED)
000= <1
100= >100

PATWT
Weight,
CSTRATM
Stratum, and
CPSUM
Cluster variables
1. 314.00, denotes “Attention deficit disorder without mention of hyperactivity”; 314.01
denotes “Attention deficit disorder with hyperactivity”.
2. For full list of comorbidities, see Appendix C.
3. Drug utilization information is captured via generic drug mentions in DRUGID1 and also the
MED1 variable. For a comprehensive list of medication variables in the NAMCS, see the table
below.
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Appendix B. Drug Codes for Psychostimulant and Non-stimulant ADHD Medications in the
2012 NAMCS
Brand Name1
Generic Name1,2
Amphetamine Psychostimulants
'95016'='ADDERALL'
'03279'='AMPHETAMINE SALT COMBO
'd04035'='AMPHETAMINE-DEXTROAMPHETAMINE'
'10389'='DEXTROAMPHETAMINE/AMPHETAMINE'
'd00803'='AMPHETAMINE'
'01660'='AMPHETAMINE'
'01281'='ADDERALL XR'

Amphetamine, dextroamphetamine mixed salts

'07406'='VYVANSE'

'd06663'='LISDEXAMFETAMINE'

Methylphenidate Psychostimulants
'26760'='RITALIN'
'19175'='METHYLPHENIDATE'
'd00900'='METHYLPHENIDATE'
'02271'='RITALIN LA'
MPH HCl E-R capsules
'01234'='RITALIN-SR'
'00233'='CONCERTA'
'06172'='DAYTRANA'
'01249'='METADATE CD'
'02018'='FOCALIN'

MPH HCl
MPH HCl E-R tablets
Methylphenidate transdermal
MPH HCl E-R capsules
'09384'='DEXMETHYLPHENIDATE'
'd04777'='DEXMETHYLPHENIDATE'
MPH HCl E-R capsules

'06004'='FOCALIN XR'
Non-Stimulant Medications
'03080'='STRATTERA'
'd04827'='ATOMOXETINE'
'03237'='ATOMOXETINE HCL'
'09396'='INTUNIV (ER)
'd00717'='GUANFACINE'
'30777'='TENEX'' (IR)
'97089'='GUANFACINE'
'05895'='CATAPRES'
'06985'='CLONIDINE'
'12129'='KAPVAY'
1
Med Cod variable includes brand names and generics. MEDCOD1-8 has values 00000-99999.
Note: Med Cod values do NOT have a lower-case "d".
2
Drug ID is the generic coding variable. DRUGID1-8 has values in the range: d00000-d99999.
Note: DrugID values do have a lower-case "d".
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Appendix C. Diagnosis Variables and Codes in NAMCS
Diagnosis Variable
Variable Values (DIAG1-DIAG3) (ICD-9)
Names
ADHD
DIAG
31400, 31401
Depressi
on18,19

DIAG
DEPRN

Asthma

Anxiety20

DIAG
ASTHMA
DIAG
OBESITY
DIAG

Autism

DIAG

Obesity

'29620','29621','29622','29623','29624'
,'29625','29626',
'29630','29631','29632','29633','29634'
,'29635','29636',
'2980', '3004-', '3091','311'
49390, 49392, 49391
2780-, 27800, 27801

Notes
00=predom IA
01= PH or CT
If DEPRN = 2 then
Depression=Y
(From a specific
survey question
screening)
If ASTHMA = 2
then Asthma=Y
If OBESITY = 2
then Obesity=Y

'30000','30001','30002','30009','30020'
,'30021','30022','30023',
'30029','3003-','308','30924','30928','30981'
29900 29901

Appendix D. Parametric Assessment of Age Variable vs. SR Stimulant Code
Analysis of Maximum Likelihood Estimates
Parameter
DF Estimate Standard Wald
Pr > ChiSq
Error
Chi-Square
Intercept
1
0.1969
0.4473
0.1937
0.6598
AGEN
2 1
0.8233
0.4951
2.7648
0.0964
AGEN
3 1
1.0845
0.5099
4.5240
0.0334
Note: AGEN=1 indicates age 4-6, AGEN=2 indicates age 7-11, AGEN=3 indicates age 12-17.
Since the beta estimates are for the three age categories are 0, 0.82, and 1.08, we are not
confident that there is a parametric relationship with age and SR medication code.

Parametric Assessment of Age Category via
Plotted SR Odds Ratios
1.2
1
0.8

1.0845
1

0.6

0.8233

0.4
0.2
0
4 to 6

7 to 11

12 to 17

Age Category
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Appendix E. Hosmer-Lemeshow Goodness of Fit Test
Since proc surveylogistic cannot perform a Hosmer-Lemeshow test and is needed to
produce nationally representative estimates for survey data, an identical model in proc
logistic was constructed so that a test could be performed. Hosmer-Lemeshow tests are
presented below for both the initial and reduced multivariate models.

Initial Multivariate Models (Table 4) GOF:
Hosmer and Lemeshow
Goodness-of-Fit
Test
ChiSquare

DF

Pr > ChiSq

11.1121

8

0.1954

47

BIBLIOGRAPHY
1.
Association AP. Diagnostic and statistical manual of mental disorders, (DSM-5®):
American Psychiatric Pub; 2013.
2.

Weyandt LL. An ADHD primer: ERIC; 2007.

3.
Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attentiondeficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics
2015;135:e994-1001.
4.
Maia CR, Cortese S, Caye A, et al. Long-Term Efficacy of Methylphenidate ImmediateRelease for the Treatment of Childhood ADHD: A Systematic Review and Meta-Analysis. J
Atten Disord 2014.
5.
Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients
with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child
Adolesc Psychiatry 2007;46:1119-27.
6.
Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit
hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc
Psychopharmacol 2004;14:575-81.
7.
Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care
provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States,
2003-2011. J Am Acad Child Adolesc Psychiatry 2014;53:34-46 e2.
8.
Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence
estimates across three decades: an updated systematic review and meta-regression analysis.
Int J Epidemiol 2014;43:434-42.
9.
Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive
children: adaptive functioning in major life activities. Journal of the American Academy of
Child & Adolescent Psychiatry 2006;45:192-202.
10.
Dittmann RW, Banaschewski T, Schacht A, Wehmeier PM. Findings from the
observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHDrelated difficulties, and patients' emotional expression during psychostimulant or
nonstimulant ADHD treatment. Atten Defic Hyperact Disord 2014;6:291-302.

48

11.
Larson K, Russ SA, Kahn RS, Halfon N. Patterns of comorbidity, functioning, and
service use for US children with ADHD, 2007. Pediatrics 2011;127:462-70.
12.
Strine TW, Lesesne CA, Okoro CA, et al. Emotional and behavioral difficulties and
impairments in everyday functioning among children with a history of attentiondeficit/hyperactivity disorder. Prev Chronic Dis 2006;3:A52.
13.
Zoega H, Valdimarsdottir UA, Hernandez-Diaz S. Age, academic performance, and
stimulant prescribing for ADHD: a nationwide cohort study. Pediatrics 2012;130:1012-8.
14.
Zoega H, Rothman KJ, Huybrechts KF, et al. A population-based study of stimulant
drug treatment of ADHD and academic progress in children. Pediatrics 2012;130:e53-62.
15.
Cuffe SP, Moore CG, McKeown R. ADHD and health services utilization in the national
health interview survey. J Atten Disord 2009;12:330-40.
16.
Lavigne JV, Lebailly SA, Hopkins J, Gouze KR, Binns HJ. The prevalence of ADHD, ODD,
depression, and anxiety in a community sample of 4-year-olds. J Clin Child Adolesc Psychol
2009;38:315-28.
17.
Merikangas KR, He JP, Brody D, Fisher PW, Bourdon K, Koretz DS. Prevalence and
treatment of mental disorders among US children in the 2001-2004 NHANES. Pediatrics
2010;125:75-81.
18.
Zenlea IS, Milliren CE, Mednick L, Rhodes ET. Depression screening in adolescents in
the United States: a national study of ambulatory office-based practice. Acad Pediatr
2014;14:186-91.
19.
Stafford RS, Ausiello JC, Misra B, Saglam D. National Patterns of Depression
Treatment in Primary Care. Prim Care Companion J Clin Psychiatry 2000;2:211-6.
20.
Harman JS, Rollman BL, Hanusa BH, Lenze EJ, Shear MK. Physician office visits of
adults for anxiety disorders in the United States, 1985-1998. J Gen Intern Med 2002;17:16572.
21.
Kawatkar AA, Knight TK, Moss RA, et al. Impact of Mental Health Comorbidities on
Health Care Utilization and Expenditure in a Large US Managed Care Adult Population with
ADHD. Value in Health 2014;17:661-8.

49

22.
Kim J, Mutyala B, Agiovlasitis S, Fernhall B. Health behaviors and obesity among US
children with attention deficit hyperactivity disorder by gender and medication use. Prev
Med 2011;52:218-22.
23.
ATTENTION-DEFICIT SO. ADHD: clinical practice guideline for the diagnosis,
evaluation, and treatment of attention-deficit/hyperactivity disorder in children and
adolescents. Pediatrics 2011:peds. 2011-654.
24.
Bradley C. THE BEHAVIOR OF CHILDREN RECEIVING BENZEDRINE. American Journal
of Psychiatry 1937;94:577-85.
25.
Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit
hyperactivity disorder. Atten Defic Hyperact Disord 2010;2:241-55.
26.
Jensen PS, Garcia JA, Glied S, et al. Cost-effectiveness of ADHD treatments: findings
from the multimodal treatment study of children with ADHD. Am J Psychiatry
2005;162:1628-36.
27.
Polanczyk G, Faraone SV, Bau CH, et al. The impact of individual and methodological
factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies
from four different continents. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1419-24.
28.
Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release
methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the
laboratory school (the Comacs Study). Pediatrics 2004;113:e206-e16.
29.
Weyandt LL, Oster DR, Marraccini ME, et al. Pharmacological interventions for
adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of
prescription stimulants. Psychol Res Behav Manag 2014;7:223-49.
30.
Dupaul GJ, Weyandt LL, Rossi JS, et al. Double-blind, placebo-controlled, crossover
study of the efficacy and safety of lisdexamfetamine dimesylate in college students with
ADHD. J Atten Disord 2012;16:202-20.
31.
Report NIoHCDC. Diagnosis and treatment of attention deficit hyperactivity disorder
(ADHD). Journal of Pharmaceutical Care in Pain & Symptom Control 2000;8:75-89.
32.
Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost
effectiveness and resource allocation 2005;3:1.

50

33.
Group MC. National Institute of Mental Health Multimodal Treatment Study of ADHD
follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity
disorder. Pediatrics 2004;113:754-61.
34.
Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Nonstimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004;13 Suppl
1:I102-16.
35.
Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of
atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 2009;29:561-4.
36.
Saloner B, Fullerton C, McGuire T. The impact of long-acting medications on
attention-deficit/hyperactivity disorder treatment disparities. J Child Adolesc
Psychopharmacol 2013;23:401-9.
37.
Mercer M, Farver D. ADHD: monitoring for and managing stimulant adverse effects. S
D Med 2013;66:511, 3.
38.
Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and
cost among Texas Medicaid children. Curr Med Res Opin 2011;27 Suppl 2:13-22.
39.
Lang HC, Scheffler RM, Hu TW. The discrepancy in attention deficit hyperactivity
disorder (ADHD) medications diffusion: 1994-2003--a global pharmaceutical data analysis.
Health Policy 2010;97:71-8.
40.
Brams M, Moon E, Pucci M, Lopez FA. Duration of effect of oral long-acting stimulant
medications for ADHD throughout the day. Curr Med Res Opin 2010;26:1809-25.
41.
Currie J, Stabile M, Jones L. Do stimulant medications improve educational and
behavioral outcomes for children with ADHD? J Health Econ 2014;37:58-69.
42.
Faraone SV. Stimulant therapy in the management of ADHD: mixed amphetamine
salts (extended release). Expert Opin Pharmacother 2007;8:2127-34.
43.
Pelham WE, Smith BH, Evans SW, et al. The Effectiveness of Short- and Long-Acting
Stimulant Medications for Adolescents With ADHD in a Naturalistic Secondary School Setting.
J Atten Disord 2013.

51

44.
Spencer TJ, Brown A, Seidman LJ, et al. Effect of psychostimulants on brain structure
and function in ADHD: a qualitative literature review of magnetic resonance imaging-based
neuroimaging studies. J Clin Psychiatry 2013;74:902-17.
45.
Toh S. Datapoints: Trends in ADHD and stimulant use among children, 1993-2003.
Psychiatric Services 2006;57:1091.
46.
Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication
treatment for ADHD. J Atten Disord 2007;10:335-42.
47.
Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of
outpatient prescription drug utilization in US children, 2002-2010. Pediatrics 2012;130:23-31.
48.
Lingineni RK, Biswas S, Ahmad N, Jackson BE, Bae S, Singh KP. Factors associated with
attention deficit/hyperactivity disorder among US children: results from a national survey.
BMC Pediatr 2012;12:50.
49.
Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence,
recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of
US children. Arch Pediatr Adolesc Med 2007;161:857-64.
50.
Stevens J, Harman JS, Kelleher KJ. Ethnic and regional differences in primary care
visits for attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004;25:318-25.
51.
Gormez V, Avery B, Mann H. Switching from immediate release to sustained release
methylphenidate in the treatment of children and adolescents with attention
deficit/hyperactivity disorder. Eur Rev Med Pharmacol Sci 2013;17:2345-9.
52.
Thompson AE, Nazir SA, Abbas MJ, Clarke J. Switching from immediate-to sustainedrelease psychostimulants in routine treatment of children with attention-deficit hyperactivity
disorder. Psychiatric Bulletin 2006;30:247-50.
53.
Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized,
controlled effectiveness trial of OROS-methylphenidate compared to usual care with
immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin
Pharmacol 2006;13:e50-62.
54.
Feldman M, Belanger S. Extended-release medications for children and adolescents
with attention-deficit hyperactivity disorder. Paediatr Child Health 2009;14:593-602.

52

55.
Health NCCfM. Attention deficit hyperactivity disorder: diagnosis and management
of ADHD in children, young people and adults: British Psychological Society (UK); 2009.
56.
Cortese S, Angriman M, Maffeis C, et al. Attention-deficit/hyperactivity disorder
(ADHD) and obesity: a systematic review of the literature. Critical reviews in food science and
nutrition 2008;48:524-37.
57.
Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism
spectrum disorders on stimulant response in children with attention deficit hyperactivity
disorder: a retrospective and prospective effectiveness study. Child Care Health Dev
2006;32:575-83.
58.
Hosmer Jr DW, Rodney X. S. Applied Logistic Regression. 3 ed. ed: John Wiley & Sons;
2013.
59.
Mickey RM, Greenland S. The impact of confounder selection criteria on effect
estimation. Am J Epidemiol 1989;129:125-37.

53

